undamentalytics Newsletter
Sign in

Tandem Diabetes Care Inc cash flow statement

In fiscal 2025, Tandem Diabetes Care Inc's operations generated −$9.7m of cash; it spent $19.9m on capital projects, leaving free cash flow of −$29.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−33−48−61−59−61−66−8422511150−3224−10−6
Depreciation and amortisation2345576610141416171818
Stock-based pay04151312132458586185881019273
Capital spending54469632027143427192021
Free cash flow−38−52−66−65−70−72−1122−39716−595−30−27
Free cash flow after stock pay−38−56−81−78−82−84−35−36−6136−69−147−96−122−99
Share buybacks——————————00300—
Shares issued0343212246751174−7——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: INSP vs TNDMTNDM vs VREXATEC vs TNDM

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Tandem Diabetes Care Inc's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tandem Diabetes Care Inc.